Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7918239 | 0.91 | RAD52 (0.36) | KDM4EHTTGRM2RAD52MAPT | |
| SCHEMBL7928160 | 0.88 | GRM2 (0.48) | KDM4EGRM2RAD52 | |
| SCHEMBL7922728 | 0.88 | GRM2 (0.36) | KDM4EHTTGRM2RAD52MAPT | |
| SCHEMBL7924595 | 0.88 | GRM2 (0.48) | KDM4EGRM2RAD52 | |
| SCHEMBL7915024 | 0.84 | GRM2 (0.32) | KDM4EGRM2RAD52MAPTALDH1A1 | |
| SCHEMBL7927257 | 0.84 | GRM2 (0.32) | KDM4EGRM2RAD52MAPTALDH1A1 | |
| SCHEMBL2174198 | 0.83 | GRM2 (0.38) | KDM4EGRM2ALDH1A1 | |
| SCHEMBL12441184 | 0.83 | ALDH1A1 (0.36) | KDM4EGRM2MAPTALDH1A1HSD17B10 | |
| SCHEMBL2188670 | 0.82 | ALDH1A1 (0.37) | KDM4EGRM2MAPTALDH1A1HSD17B10 | |
| SCHEMBL2171455 | 0.76 | GRM2 (0.38) | KDM4EGRM2ALDH1A1HSD17B10PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010036544-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | KDM4E 2667/4885HTT 740/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.